Betibeglogene autotemcel
Zynteglo (betibeglogene autotemcel) is a gene pharmaceutical. Betibeglogene autotemcel was first approved as Zynteglo on 2019-05-29. It has been approved in Europe to treat beta-thalassemia.
| Trade Name | Zynteglo |
|---|---|
| Common Name | Betibeglogene autotemcel |
| Indication | beta-thalassemia |
| Drug Class |
